Ischemic preconditioning prevents ischemia-induced beta-adrenergic receptor sequestration.
Preconditioning enables endogenous protection to repeated myocardial ischemia. However, the effect of preconditioning on beta1 adrenergic receptor (AR) signal remains controversial. We have recently developed receptor assay system using whole cells, in which overexpressed cell surface beta ARs can be readily quantitated without disrupting the cell. Using this technique, we examined the effects of chemical/metabolic ischemia on the beta1 AR sequestration and adenylyl cyclase activity. Isoproterenol treatment, but not forskolin treatment, of HEK293T cells overexpressing beta1 ARs led to a rapid decrease (within 2 hours) in the number of the cell surface receptor, which was negated in the presence of concanavalin A. Similarly, treatment of cells with potassium cyanide and 2-deoxy-D-glucose (chemical/metabolic ischemia) induced similar receptor sequestration. When isoproterenol was superimposed on chemical/metabolic ischemia, the degree of sequestration became greater. However, when cells were pre-exposed to potassium cyanide on the preceding day (chemical preconditioning), the sequestration induced by either isoproterenol or chemical/metabolic ischemia was attenuated. Adenylyl cyclase catalytic activity as assessed by stimulation with forskolin was decreased by chemical/metabolic ischemia but fully recovered after 24 hours, suggesting that chemical/metabolic ischemia treatment did not alter cell viability. Putting together, chemical/metabolic ischemia induced beta1 AR sequestration in a similar manner to isoproterenol. In addition, preconditioning prevented the beta1 AR sequestration induced by both isoproterenol and chemical/metabolic ischemia. Pre-conditioning may play a role in preserving the cell surface beta ARs by inhibiting the sequestration that is usually induced by an ischemic event or beta adrenergic stimulation.
Iwatsubo
Kousaku
K
Departments of Physiology and Medicine, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.
Toya
Yoshiyuki
Y
Fujita
Takayuki
T
Ebina
Toshiaki
T
Schwencke
Carsten
C
Minamisawa
Susumu
S
Umemura
Satoshi
S
Ishikawa
Yoshihiro
Y
D000262:Adenylyl Cyclases / Q000187:drug effects / Q000378:metabolism*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D002460:Cell Line; D002470:Cell Survival; D005576:Colforsin / Q000494:pharmacology; D003847:Deoxyglucose / Q000378:metabolism; D006801:Humans; D019194:Ischemic Preconditioning; D019157:Ischemic Preconditioning, Myocardial; D007545:Isoproterenol / Q000494:pharmacology; D007668:Kidney / Q000166:cytology; D017202:Myocardial Ischemia; D011190:Potassium Cyanide / Q000494:pharmacology; D011869:Radioligand Assay; D011943:Receptors, Adrenergic, beta / Q000032:analysis / Q000187:drug effects / Q000378:metabolism*
D000318:Adrenergic beta-Agonists; D011943:Receptors, Adrenergic, beta; D005576:Colforsin; D003847:Deoxyglucose; D000262:Adenylyl Cyclases; D007545:Isoproterenol; D011190:Potassium Cyanide